23 February 2009
Dupuytren’s contracture and phenobarbital: Our case reports and review of the literature
Massimiliano Tripoli, Adriana Cordova, Pietro Napoli, Mario Cherubino, Francesco MoschellaAm J Case Rep 2009; 10:18-21 :: ID: 869590
Abstract
Background: Dupuytren’s contracture is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren’s disease. In our this retrospective study the association between phenobarbital and Dupuytren’s contracture is discussed.
Case Reports: Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren’s contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren’s disease showed different evolutions in relation to dosage and type of antiepileptic drug used.
Conclusions: We believe that phenobarbital causes a dose and time-dipendent profibrotic effect. We notice a clinical regression when phenobarbital was substituted by carbamazepine, maintaining the same dose (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren’s recurrence.
Keywords: Dupuytren's Contracture, Phenobarbital, Epilepsy
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






